A Phase 1, Open-label Study to Assess the Mass Balance, Metabolism, Excretion and Pharmacokinetics of a Single Subcutaneous Dose of [14C]-ITI-1284 in Healthy Male Subjects
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Lumateperone (Primary)
- Indications Agitation; Generalised anxiety disorder; Psychotic disorders
- Focus Pharmacokinetics
- Sponsors Intra-Cellular Therapies
- 29 Jan 2025 New trial record